Literature DB >> 35046096

RAS at 40: Update from the RAS Initiative.

Dwight V Nissley1, Frank McCormick2.   

Abstract

SUMMARY: The RAS Initiative was launched in 2013 to address unmet clinical needs of patients with KRAS-driven cancers. The Initiative is based at Frederick National Laboratory for Cancer Research in Frederick, MD, and involves multiple collaborations with the RAS research community in academia and industry with the shared goal of developing RAS therapies. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35046096     DOI: 10.1158/2159-8290.CD-21-1554

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  3 in total

Review 1.  Small molecule inhibitors targeting the cancers.

Authors:  Gui-Hong Liu; Tao Chen; Xin Zhang; Xue-Lei Ma; Hua-Shan Shi
Journal:  MedComm (2020)       Date:  2022-10-13

2.  Understanding and drugging RAS: 40 years to break the tip of the iceberg.

Authors:  Donita C Brady; Julija Hmeljak; Arvin C Dar
Journal:  Dis Model Mech       Date:  2022-03-04       Impact factor: 5.758

Review 3.  Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner.

Authors:  Christophe Bontoux; Véronique Hofman; Patrick Brest; Marius Ilié; Baharia Mograbi; Paul Hofman
Journal:  Cancers (Basel)       Date:  2022-03-23       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.